drugset
drugset / Trial / NCT05074355

Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms

NCT05074355 ↗

Phase 2 Recruiting 40 enrolled University Health Network, Toronto
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to look at how safe and useful a drug called azacitidine in combination with a drug called venetoclax, is in people with accelerated or blast phase BRC-ABL negative myeloproliferative neoplasms.

Timeline

Start
2023-11-08
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified — Subcutaneous
Subject Venetoclax Small molecule 400 mg Oral

Indications

myeloproliferative neoplasm